Cancer drugs are often effective at killing cancer cells, but they can also cause severe side effects. One of the most common side effects is hair loss, which can be devastating for patients.
A new study from the University of California, San Francisco (UCSF) has identified an enzyme that is responsible for hair loss caused by cancer drugs. The enzyme, called tyrosyl-DNA phosphodiesterase 1 (TDP1), is found in the nucleus of cells. When cancer drugs damage DNA, TDP1 helps to repair the damage. However, TDP1 can also bind to and damage healthy DNA, leading to cell death.
The researchers found that TDP1 is more active in cancer cells than in healthy cells. This means that cancer cells are more likely to be damaged by TDP1 when they are exposed to cancer drugs.
The study findings could lead to the development of new drugs that inhibit TDP1 and protect healthy cells from damage. This could reduce the side effects of cancer drugs and make them more tolerable for patients.
The enzyme TDP1
TDP1 is a member of the phosphodiesterase family of enzymes. Phosphodiesterases cleave the phosphodiester bond between two nucleotides in a DNA or RNA molecule. TDP1 specifically cleaves the phosphodiester bond between a tyrosine nucleotide and a DNA nucleotide.
TDP1 is involved in a number of cellular processes, including DNA repair, transcription, and RNA processing. In DNA repair, TDP1 helps to remove damaged nucleotides from DNA so that they can be replaced with new nucleotides. In transcription, TDP1 helps to cleave the RNA molecule from the DNA template. In RNA processing, TDP1 helps to remove introns from RNA molecules so that they can be translated into proteins.
TDP1 and cancer drugs
Cancer drugs can damage DNA in a number of ways. Some cancer drugs, such as cisplatin and doxorubicin, intercalate into DNA and prevent it from replicating. Other cancer drugs, such as topoisomerase inhibitors, cause DNA strand breaks.
When DNA is damaged, TDP1 helps to repair the damage. However, TDP1 can also bind to and damage healthy DNA. This can lead to cell death and the side effects of cancer drugs.
The study findings
The UCSF researchers found that TDP1 is more active in cancer cells than in healthy cells. This means that cancer cells are more likely to be damaged by TDP1 when they are exposed to cancer drugs.
The researchers also found that TDP1 inhibitors can protect healthy cells from the side effects of cancer drugs. In a mouse model, TDP1 inhibitors reduced hair loss and other side effects caused by cisplatin and doxorubicin.
The implications of the study findings
The study findings could lead to the development of new drugs that inhibit TDP1 and protect healthy cells from the side effects of cancer drugs. This could make cancer drugs more tolerable for patients and improve their quality of life.
Further research
Further research is needed to develop TDP1 inhibitors that are safe and effective for use in humans. The researchers are currently conducting clinical trials of TDP1 inhibitors in patients with cancer.
